Global Biosimilar Monoclonal Antibodies Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
According to our (Global Info Research) latest study, the global Biosimilar Monoclonal Antibodies market size was valued at US$ 5475 million in 2023 and is forecast to a readjusted size of USD 14970 million by 2030 with a CAGR of 15.6% during review period.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
This report is a detailed and comprehensive analysis for global Biosimilar Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Biosimilar Monoclonal Antibodies market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosimilar Monoclonal Antibodies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosimilar Monoclonal Antibodies market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Biosimilar Monoclonal Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilar Monoclonal Antibodies, with price, sales quantity, revenue, and global market share of Biosimilar Monoclonal Antibodies from 2019 to 2024.
Chapter 3, the Biosimilar Monoclonal Antibodies competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Biosimilar Monoclonal Antibodies market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Monoclonal Antibodies.
Chapter 14 and 15, to describe Biosimilar Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.
Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.
According to our (Global Info Research) latest study, the global Biosimilar Monoclonal Antibodies market size was valued at US$ 5475 million in 2023 and is forecast to a readjusted size of USD 14970 million by 2030 with a CAGR of 15.6% during review period.
Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.
Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.
In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.
This report is a detailed and comprehensive analysis for global Biosimilar Monoclonal Antibodies market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Biosimilar Monoclonal Antibodies market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030
Global Biosimilar Monoclonal Antibodies market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biosimilar Monoclonal Antibodies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biosimilar Monoclonal Antibodies market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy’s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma, Torrent Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Biosimilar Monoclonal Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Infliximab
- Rituximab
- Trastuzumab
- Adalimumab
- Other
- Oncology
- Autoimmune Disease
- Other
- Celltrion
- Pfizer (Hospira)
- 3SBIO
- Novartis (Sandoz)
- Dr Reddy’s
- Celgen Biopharma
- Cadila Healthcare
- Hisun Pharma
- Torrent Pharmaceuticals
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Biosimilar Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Biosimilar Monoclonal Antibodies, with price, sales quantity, revenue, and global market share of Biosimilar Monoclonal Antibodies from 2019 to 2024.
Chapter 3, the Biosimilar Monoclonal Antibodies competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Biosimilar Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Biosimilar Monoclonal Antibodies market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Monoclonal Antibodies.
Chapter 14 and 15, to describe Biosimilar Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Infliximab
1.3.3 Rituximab
1.3.4 Trastuzumab
1.3.5 Adalimumab
1.3.6 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oncology
1.4.3 Autoimmune Disease
1.4.4 Other
1.5 Global Biosimilar Monoclonal Antibodies Market Size & Forecast
1.5.1 Global Biosimilar Monoclonal Antibodies Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030)
1.5.3 Global Biosimilar Monoclonal Antibodies Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Biosimilar Monoclonal Antibodies Product and Services
2.1.4 Celltrion Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Celltrion Recent Developments/Updates
2.2 Pfizer (Hospira)
2.2.1 Pfizer (Hospira) Details
2.2.2 Pfizer (Hospira) Major Business
2.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
2.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Pfizer (Hospira) Recent Developments/Updates
2.3 3SBIO
2.3.1 3SBIO Details
2.3.2 3SBIO Major Business
2.3.3 3SBIO Biosimilar Monoclonal Antibodies Product and Services
2.3.4 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 3SBIO Recent Developments/Updates
2.4 Novartis (Sandoz)
2.4.1 Novartis (Sandoz) Details
2.4.2 Novartis (Sandoz) Major Business
2.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
2.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis (Sandoz) Recent Developments/Updates
2.5 Dr Reddy’s
2.5.1 Dr Reddy’s Details
2.5.2 Dr Reddy’s Major Business
2.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
2.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Dr Reddy’s Recent Developments/Updates
2.6 Celgen Biopharma
2.6.1 Celgen Biopharma Details
2.6.2 Celgen Biopharma Major Business
2.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
2.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Celgen Biopharma Recent Developments/Updates
2.7 Cadila Healthcare
2.7.1 Cadila Healthcare Details
2.7.2 Cadila Healthcare Major Business
2.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
2.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Cadila Healthcare Recent Developments/Updates
2.8 Hisun Pharma
2.8.1 Hisun Pharma Details
2.8.2 Hisun Pharma Major Business
2.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
2.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Hisun Pharma Recent Developments/Updates
2.9 Torrent Pharmaceuticals
2.9.1 Torrent Pharmaceuticals Details
2.9.2 Torrent Pharmaceuticals Major Business
2.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
2.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Torrent Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: BIOSIMILAR MONOCLONAL ANTIBODIES BY MANUFACTURER
3.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024)
3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024)
3.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
3.4.3 Top 6 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
3.5 Biosimilar Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.5.1 Biosimilar Monoclonal Antibodies Market: Region Footprint
3.5.2 Biosimilar Monoclonal Antibodies Market: Company Product Type Footprint
3.5.3 Biosimilar Monoclonal Antibodies Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Biosimilar Monoclonal Antibodies Market Size by Region
4.1.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
4.1.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
4.1.3 Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2030)
4.2 North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.3 Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.4 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.5 South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.6 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
5.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2019-2030)
5.3 Global Biosimilar Monoclonal Antibodies Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
6.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2030)
6.3 Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
7.2 North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
7.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
7.3.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
7.3.2 North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
8.2 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
8.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
8.3.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
8.3.2 Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Region
9.3.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
10.2 South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
10.3 South America Biosimilar Monoclonal Antibodies Market Size by Country
10.3.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
10.3.2 South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Biosimilar Monoclonal Antibodies Market Size by Country
11.3.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Biosimilar Monoclonal Antibodies Market Drivers
12.2 Biosimilar Monoclonal Antibodies Market Restraints
12.3 Biosimilar Monoclonal Antibodies Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Biosimilar Monoclonal Antibodies and Key Manufacturers
13.2 Manufacturing Costs Percentage of Biosimilar Monoclonal Antibodies
13.3 Biosimilar Monoclonal Antibodies Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Biosimilar Monoclonal Antibodies Typical Distributors
14.3 Biosimilar Monoclonal Antibodies Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OFTABLES
Table 1. Global Biosimilar Monoclonal Antibodies Consumption Value byType, (USD Million), 2019 & 2023 & 2030
Table 2. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Biosimilar Monoclonal Antibodies Product and Services
Table 6. Celltrion Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Celltrion Recent Developments/Updates
Table 8. Pfizer (Hospira) Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer (Hospira) Major Business
Table 10. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
Table 11. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Pfizer (Hospira) Recent Developments/Updates
Table 13. 3SBIO Basic Information, Manufacturing Base and Competitors
Table 14. 3SBIO Major Business
Table 15. 3SBIO Biosimilar Monoclonal Antibodies Product and Services
Table 16. 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. 3SBIO Recent Developments/Updates
Table 18. Novartis (Sandoz) Basic Information, Manufacturing Base and Competitors
Table 19. Novartis (Sandoz) Major Business
Table 20. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
Table 21. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis (Sandoz) Recent Developments/Updates
Table 23. Dr Reddy’s Basic Information, Manufacturing Base and Competitors
Table 24. Dr Reddy’s Major Business
Table 25. Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
Table 26. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Dr Reddy’s Recent Developments/Updates
Table 28. Celgen Biopharma Basic Information, Manufacturing Base and Competitors
Table 29. Celgen Biopharma Major Business
Table 30. Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
Table 31. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Celgen Biopharma Recent Developments/Updates
Table 33. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 34. Cadila Healthcare Major Business
Table 35. Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
Table 36. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Cadila Healthcare Recent Developments/Updates
Table 38. Hisun Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Hisun Pharma Major Business
Table 40. Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
Table 41. Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Hisun Pharma Recent Developments/Updates
Table 43.Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44.Torrent Pharmaceuticals Major Business
Table 45.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
Table 46.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47.Torrent Pharmaceuticals Recent Developments/Updates
Table 48. Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 49. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024) & (USD Million)
Table 50. Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 51. Market Position of Manufacturers in Biosimilar Monoclonal Antibodies, (Tier 1,Tier 2, andTier 3), Based on Revenue in 2023
Table 52. Head Office and Biosimilar Monoclonal Antibodies Production Site of Key Manufacturer
Table 53. Biosimilar Monoclonal Antibodies Market: Company ProductTypeFootprint
Table 54. Biosimilar Monoclonal Antibodies Market: Company Product ApplicationFootprint
Table 55. Biosimilar Monoclonal Antibodies New Market Entrants and Barriers to Market Entry
Table 56. Biosimilar Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 58. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 59. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 60. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 61. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 62. Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2024) & (USD/Unit)
Table 63. Global Biosimilar Monoclonal Antibodies Average Price by Region (2025-2030) & (USD/Unit)
Table 64. Global Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 65. Global Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 66. Global Biosimilar Monoclonal Antibodies Consumption Value byType (2019-2024) & (USD Million)
Table 67. Global Biosimilar Monoclonal Antibodies Consumption Value byType (2025-2030) & (USD Million)
Table 68. Global Biosimilar Monoclonal Antibodies Average Price byType (2019-2024) & (USD/Unit)
Table 69. Global Biosimilar Monoclonal Antibodies Average Price byType (2025-2030) & (USD/Unit)
Table 70. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 71. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 72. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
Table 73. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
Table 74. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2024) & (USD/Unit)
Table 75. Global Biosimilar Monoclonal Antibodies Average Price by Application (2025-2030) & (USD/Unit)
Table 76. North America Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 77. North America Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 78. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 79. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 80. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 81. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 82. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 83. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 84. Europe Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 85. Europe Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 86. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 87. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 88. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 89. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 90. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 91. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 92. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 93. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 94. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 95. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 96. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 97. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 98. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 99. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 100. South America Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 101. South America Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 102. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 103. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 104. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 105. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 106. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 107. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 108. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 109. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 110. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 111. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 112. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 113. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 114. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 115. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 116. Biosimilar Monoclonal Antibodies Raw Material
Table 117. Key Manufacturers of Biosimilar Monoclonal Antibodies Raw Materials
Table 118. Biosimilar Monoclonal AntibodiesTypical Distributors
Table 119. Biosimilar Monoclonal AntibodiesTypical Customers
LIST OFFIGURES
Figure 1. Biosimilar Monoclonal Antibodies Picture
Figure 2. Global Biosimilar Monoclonal Antibodies Revenue byType, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Biosimilar Monoclonal Antibodies Revenue Market Share byType in 2023
Figure 4. Infliximab Examples
Figure 5. Rituximab Examples
Figure 6.Trastuzumab Examples
Figure 7. Adalimumab Examples
Figure 8. Other Examples
Figure 9. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 10. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application in 2023
Figure 11. Oncology Examples
Figure 12. Autoimmune Disease Examples
Figure 13. Other Examples
Figure 14. Global Biosimilar Monoclonal Antibodies Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 15. Global Biosimilar Monoclonal Antibodies Consumption Value andForecast (2019-2030) & (USD Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030) & (K Units)
Figure 17. Global Biosimilar Monoclonal Antibodies Price (2019-2030) & (USD/Unit)
Figure 18. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Manufacturer in 2023
Figure 19. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturer in 2023
Figure 20. Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 21.Top 3 Biosimilar Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
Figure 22.Top 6 Biosimilar Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
Figure 23. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 24. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 25. North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 26. Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 27. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 28. South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 29. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 30. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 31. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share byType (2019-2030)
Figure 32. Global Biosimilar Monoclonal Antibodies Average Price byType (2019-2030) & (USD/Unit)
Figure 33. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 34. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
Figure 35. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030) & (USD/Unit)
Figure 36. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 37. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 38. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 39. North America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 40. United States Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 41. Canada Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 42. Mexico Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 43. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 44. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 45. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 46. Europe Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 47. Germany Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 48.France Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 49. United Kingdom Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 50. Russia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 51. Italy Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 52. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 53. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 54. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 55. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 56. China Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 57. Japan Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 58. South Korea Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 59. India Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 60. Southeast Asia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 61. Australia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 62. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 63. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 64. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 65. South America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 66. Brazil Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 67. Argentina Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 68. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 69. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 70. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 71. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 72.Turkey Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 73. Egypt Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 74. Saudi Arabia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 75. South Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 76. Biosimilar Monoclonal Antibodies Market Drivers
Figure 77. Biosimilar Monoclonal Antibodies Market Restraints
Figure 78. Biosimilar Monoclonal Antibodies MarketTrends
Figure 79. PortersFiveForces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Biosimilar Monoclonal Antibodies in 2023
Figure 81. Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
Figure 82. Biosimilar Monoclonal Antibodies Industrial Chain
Figure 83. Sales Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Infliximab
1.3.3 Rituximab
1.3.4 Trastuzumab
1.3.5 Adalimumab
1.3.6 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oncology
1.4.3 Autoimmune Disease
1.4.4 Other
1.5 Global Biosimilar Monoclonal Antibodies Market Size & Forecast
1.5.1 Global Biosimilar Monoclonal Antibodies Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030)
1.5.3 Global Biosimilar Monoclonal Antibodies Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Biosimilar Monoclonal Antibodies Product and Services
2.1.4 Celltrion Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Celltrion Recent Developments/Updates
2.2 Pfizer (Hospira)
2.2.1 Pfizer (Hospira) Details
2.2.2 Pfizer (Hospira) Major Business
2.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
2.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Pfizer (Hospira) Recent Developments/Updates
2.3 3SBIO
2.3.1 3SBIO Details
2.3.2 3SBIO Major Business
2.3.3 3SBIO Biosimilar Monoclonal Antibodies Product and Services
2.3.4 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 3SBIO Recent Developments/Updates
2.4 Novartis (Sandoz)
2.4.1 Novartis (Sandoz) Details
2.4.2 Novartis (Sandoz) Major Business
2.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
2.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Novartis (Sandoz) Recent Developments/Updates
2.5 Dr Reddy’s
2.5.1 Dr Reddy’s Details
2.5.2 Dr Reddy’s Major Business
2.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
2.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Dr Reddy’s Recent Developments/Updates
2.6 Celgen Biopharma
2.6.1 Celgen Biopharma Details
2.6.2 Celgen Biopharma Major Business
2.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
2.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Celgen Biopharma Recent Developments/Updates
2.7 Cadila Healthcare
2.7.1 Cadila Healthcare Details
2.7.2 Cadila Healthcare Major Business
2.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
2.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Cadila Healthcare Recent Developments/Updates
2.8 Hisun Pharma
2.8.1 Hisun Pharma Details
2.8.2 Hisun Pharma Major Business
2.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
2.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Hisun Pharma Recent Developments/Updates
2.9 Torrent Pharmaceuticals
2.9.1 Torrent Pharmaceuticals Details
2.9.2 Torrent Pharmaceuticals Major Business
2.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
2.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Torrent Pharmaceuticals Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: BIOSIMILAR MONOCLONAL ANTIBODIES BY MANUFACTURER
3.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024)
3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024)
3.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
3.4.3 Top 6 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
3.5 Biosimilar Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.5.1 Biosimilar Monoclonal Antibodies Market: Region Footprint
3.5.2 Biosimilar Monoclonal Antibodies Market: Company Product Type Footprint
3.5.3 Biosimilar Monoclonal Antibodies Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Biosimilar Monoclonal Antibodies Market Size by Region
4.1.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
4.1.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
4.1.3 Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2030)
4.2 North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.3 Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.4 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.5 South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.6 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
5.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2019-2030)
5.3 Global Biosimilar Monoclonal Antibodies Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
6.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2030)
6.3 Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
7.2 North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
7.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
7.3.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
7.3.2 North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
8.2 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
8.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
8.3.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
8.3.2 Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Region
9.3.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
10.2 South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
10.3 South America Biosimilar Monoclonal Antibodies Market Size by Country
10.3.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
10.3.2 South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Biosimilar Monoclonal Antibodies Market Size by Country
11.3.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Biosimilar Monoclonal Antibodies Market Drivers
12.2 Biosimilar Monoclonal Antibodies Market Restraints
12.3 Biosimilar Monoclonal Antibodies Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Biosimilar Monoclonal Antibodies and Key Manufacturers
13.2 Manufacturing Costs Percentage of Biosimilar Monoclonal Antibodies
13.3 Biosimilar Monoclonal Antibodies Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Biosimilar Monoclonal Antibodies Typical Distributors
14.3 Biosimilar Monoclonal Antibodies Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OFTABLES
Table 1. Global Biosimilar Monoclonal Antibodies Consumption Value byType, (USD Million), 2019 & 2023 & 2030
Table 2. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Biosimilar Monoclonal Antibodies Product and Services
Table 6. Celltrion Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Celltrion Recent Developments/Updates
Table 8. Pfizer (Hospira) Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer (Hospira) Major Business
Table 10. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
Table 11. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Pfizer (Hospira) Recent Developments/Updates
Table 13. 3SBIO Basic Information, Manufacturing Base and Competitors
Table 14. 3SBIO Major Business
Table 15. 3SBIO Biosimilar Monoclonal Antibodies Product and Services
Table 16. 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. 3SBIO Recent Developments/Updates
Table 18. Novartis (Sandoz) Basic Information, Manufacturing Base and Competitors
Table 19. Novartis (Sandoz) Major Business
Table 20. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
Table 21. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis (Sandoz) Recent Developments/Updates
Table 23. Dr Reddy’s Basic Information, Manufacturing Base and Competitors
Table 24. Dr Reddy’s Major Business
Table 25. Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
Table 26. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Dr Reddy’s Recent Developments/Updates
Table 28. Celgen Biopharma Basic Information, Manufacturing Base and Competitors
Table 29. Celgen Biopharma Major Business
Table 30. Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
Table 31. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Celgen Biopharma Recent Developments/Updates
Table 33. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 34. Cadila Healthcare Major Business
Table 35. Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
Table 36. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Cadila Healthcare Recent Developments/Updates
Table 38. Hisun Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Hisun Pharma Major Business
Table 40. Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
Table 41. Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Hisun Pharma Recent Developments/Updates
Table 43.Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44.Torrent Pharmaceuticals Major Business
Table 45.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
Table 46.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47.Torrent Pharmaceuticals Recent Developments/Updates
Table 48. Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 49. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024) & (USD Million)
Table 50. Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 51. Market Position of Manufacturers in Biosimilar Monoclonal Antibodies, (Tier 1,Tier 2, andTier 3), Based on Revenue in 2023
Table 52. Head Office and Biosimilar Monoclonal Antibodies Production Site of Key Manufacturer
Table 53. Biosimilar Monoclonal Antibodies Market: Company ProductTypeFootprint
Table 54. Biosimilar Monoclonal Antibodies Market: Company Product ApplicationFootprint
Table 55. Biosimilar Monoclonal Antibodies New Market Entrants and Barriers to Market Entry
Table 56. Biosimilar Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 58. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 59. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 60. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 61. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 62. Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2024) & (USD/Unit)
Table 63. Global Biosimilar Monoclonal Antibodies Average Price by Region (2025-2030) & (USD/Unit)
Table 64. Global Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 65. Global Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 66. Global Biosimilar Monoclonal Antibodies Consumption Value byType (2019-2024) & (USD Million)
Table 67. Global Biosimilar Monoclonal Antibodies Consumption Value byType (2025-2030) & (USD Million)
Table 68. Global Biosimilar Monoclonal Antibodies Average Price byType (2019-2024) & (USD/Unit)
Table 69. Global Biosimilar Monoclonal Antibodies Average Price byType (2025-2030) & (USD/Unit)
Table 70. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 71. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 72. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
Table 73. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
Table 74. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2024) & (USD/Unit)
Table 75. Global Biosimilar Monoclonal Antibodies Average Price by Application (2025-2030) & (USD/Unit)
Table 76. North America Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 77. North America Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 78. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 79. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 80. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 81. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 82. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 83. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 84. Europe Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 85. Europe Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 86. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 87. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 88. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 89. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 90. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 91. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 92. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 93. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 94. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 95. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 96. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 97. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 98. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 99. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 100. South America Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 101. South America Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 102. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 103. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 104. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 105. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 106. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 107. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 108. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity byType (2019-2024) & (K Units)
Table 109. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity byType (2025-2030) & (K Units)
Table 110. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 111. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 112. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 113. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 114. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 115. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 116. Biosimilar Monoclonal Antibodies Raw Material
Table 117. Key Manufacturers of Biosimilar Monoclonal Antibodies Raw Materials
Table 118. Biosimilar Monoclonal AntibodiesTypical Distributors
Table 119. Biosimilar Monoclonal AntibodiesTypical Customers
LIST OFFIGURES
Figure 1. Biosimilar Monoclonal Antibodies Picture
Figure 2. Global Biosimilar Monoclonal Antibodies Revenue byType, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Biosimilar Monoclonal Antibodies Revenue Market Share byType in 2023
Figure 4. Infliximab Examples
Figure 5. Rituximab Examples
Figure 6.Trastuzumab Examples
Figure 7. Adalimumab Examples
Figure 8. Other Examples
Figure 9. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 10. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application in 2023
Figure 11. Oncology Examples
Figure 12. Autoimmune Disease Examples
Figure 13. Other Examples
Figure 14. Global Biosimilar Monoclonal Antibodies Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 15. Global Biosimilar Monoclonal Antibodies Consumption Value andForecast (2019-2030) & (USD Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030) & (K Units)
Figure 17. Global Biosimilar Monoclonal Antibodies Price (2019-2030) & (USD/Unit)
Figure 18. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Manufacturer in 2023
Figure 19. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturer in 2023
Figure 20. Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 21.Top 3 Biosimilar Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
Figure 22.Top 6 Biosimilar Monoclonal Antibodies Manufacturer (Revenue) Market Share in 2023
Figure 23. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 24. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 25. North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 26. Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 27. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 28. South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 29. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 30. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 31. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share byType (2019-2030)
Figure 32. Global Biosimilar Monoclonal Antibodies Average Price byType (2019-2030) & (USD/Unit)
Figure 33. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 34. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2019-2030)
Figure 35. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030) & (USD/Unit)
Figure 36. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 37. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 38. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 39. North America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 40. United States Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 41. Canada Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 42. Mexico Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 43. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 44. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 45. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 46. Europe Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 47. Germany Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 48.France Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 49. United Kingdom Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 50. Russia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 51. Italy Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 52. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 53. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 54. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 55. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 56. China Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 57. Japan Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 58. South Korea Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 59. India Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 60. Southeast Asia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 61. Australia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 62. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 63. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 64. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 65. South America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 66. Brazil Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 67. Argentina Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 68. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share byType (2019-2030)
Figure 69. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 70. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 71. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 72.Turkey Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 73. Egypt Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 74. Saudi Arabia Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 75. South Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 76. Biosimilar Monoclonal Antibodies Market Drivers
Figure 77. Biosimilar Monoclonal Antibodies Market Restraints
Figure 78. Biosimilar Monoclonal Antibodies MarketTrends
Figure 79. PortersFiveForces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Biosimilar Monoclonal Antibodies in 2023
Figure 81. Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
Figure 82. Biosimilar Monoclonal Antibodies Industrial Chain
Figure 83. Sales Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source
